Donald J. Enright

The Duvall Foundry
1050 30th Street, N.W.
Washington, DC 20007
(202) 337-8000 – T
(202) 337-8090 – F
This email address is being protected from spam bots, you need Javascript enabled to view it

Education:

George Washington Univ., J.D., 1996
Drew Univ., B.A., 1993, cum laude 

Bar Admissions:

District of Columbia, 1999
Maryland, 1996
New Jersey, 1996

Primary Practice Areas:

Commodities
Consumer Protection
Securities

This email address is being protected from spam bots, you need Javascript enabled to view it
Partner

thumb_img_0040

Donald J. Enright joined Finkelstein Thompson LLP as an associate in 1996, and became a partner in January 2004. He is a 1993 cum laude graduate of Drew University, where he earned a Bachelor of Arts in Political Science and Economics, and a 1996 graduate of the George Washington University Law School, where he received his Juris Doctor. He was a Member Editor of The George Washington University Journal of International Law and Economics from 1994 to 1996, and clerked for the House Judiciary Committee in 1994. He is a member of the Bars of the District of Columbia, Maryland, and New Jersey, and is admitted to practice before several United States District Courts and Circuit Courts of Appeal.

Mr. Enright handles matters in the fields of securities, commodities, consumer fraud and commercial litigation, and on behalf of the firm represents several institutional investors in connection with the firm's shareholder litigation practice. He has a track record of achieving victories in federal trials and appeals, including Nathenson v. Zonagen, Inc. 267 F. 3d 400, 413 (5th Cir. 2001); SEC v. Butler, 2005 U.S. Dist. LEXIS 7194 (W.D. Pa. April 18, 2005); and Belizan v. Hershon, 434 F. 3d 579 (D.C. Cir. 2006).

Mr. Enright practices in the firm's Washington, DC office, and has been named as one of Washington’s "Top Lawyers" by Washingtonian magazine. His recently published securities litigation-related articles include:

  •  SEC Enforcement Actions and Investigations in Private and Public Offerings, Securities: Public and Private Offerings, Second Edition, West Publishing 2007.
  • Dura Pharmaceuticals: Loss Causation Redefined or Merely Clarified?, J. Tax'n & Reg. Fin. Inst., September/October 2007, at 5.